Review
Cardiac & Cardiovascular Systems
Jacqueline T. Vuong, Ashley F. Stein-Merlob, Richard K. Cheng, Eric H. Yang
Summary: Anthracyclines are important in the treatment of various cancers, but can have significant implications on cardiovascular health. As the number of cancer survivors increases, it becomes crucial to detect and treat anthracycline-induced cardiotoxicity. Current treatment methods are based on conventional heart failure treatment, but there is a need for specific therapies for anthracycline-induced cardiotoxicity.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Medicine, General & Internal
Keiko Inoue, Noriko Iida, Kazuko Tajiri, Hiroko Bando, Shigeru Chiba, Nobutaka Tasaka, Kenji Nagashio, Rumi Sasamura, Hiroyuki Naito, Momoko Murata, Siqi Li, Tomoko Ishizu, Yoko Nakazawa, Ikuo Sekine, Masaki Ieda
Summary: The study conducted a prospective multicenter registry study on cardiac management in patients treated with anthracyclines. Analysis of 1-year follow-up data of 97 patients showed the feasibility of the AIC registry study in Japanese patients. The study aims to collect echocardiographic and biomarker data on cardiotoxicity in a real-world setting.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Oncology
Shruti Rajesh Patel, Giselle Alexandra Suero-Abreu, Angela Ai, Maya K. K. Ramachandran, Kelly Meza, Narjust Florez
Summary: Cardio-oncology focuses on reducing cardiovascular risks, detecting and treating cardiovascular diseases in cancer patients. Disparities in cardio-oncologic care exist among different populations due to factors such as cancer screening rates, genetic risk factors, cultural stressors, tobacco exposure rates, and physical inactivity. Barriers to care also exist in minority groups and low-income populations. Urgent efforts are needed to address these disparities.
FRONTIERS IN ONCOLOGY
(2023)
Article
Cardiac & Cardiovascular Systems
Johanna E. J. Jacobs, Ipek Guler, Jurgen Duchenne, Stefan Janssens, Lucas N. L. Van Aelst
Summary: Cardiovascular morbidity and mortality are common in cancer patients and survivors, highlighting the need for adequate risk prediction tools for systematic screening and rigorous cardiovascular follow-up. Existing risk scores for cardiotoxicity are suboptimal and should be interpreted with caution.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2022)
Review
Cardiac & Cardiovascular Systems
Yinghui Wang, Yonggang Wang, Xiaorong Han, Jian Sun, Cheng Li, Binay Kumar Adhikari, Jin Zhang, Xiao Miao, Zhaoyang Chen
Summary: Cardiovascular disease (CVD) and cancer are leading causes of death worldwide. The adverse effects of anti-tumor therapy, particularly on the cardiovascular system, have gained significant attention. Incidence of cardiovascular events is higher than tumor recurrence rate, and CVD and malignant tumors share common risk factors. Clinicians should understand this relationship, provide primary and secondary prevention strategies, and follow proper treatment methods.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Biochemistry & Molecular Biology
Yu-Wei Chang, Hui-Ying Weng, Shih-Feng Tsai, Frank Sheng Fan
Summary: Anthracycline-induced cardiomyopathy is a significant issue in clinical oncology. Recent advancements have been made in identifying genetic defects associated with anthracycline-induced cardiotoxicity. This case report presents preliminary findings of a genetic study on a patient who developed cardiomyopathy after receiving anthracycline-based chemotherapy.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Cardiac & Cardiovascular Systems
Dong-Woo Kang, Rebekah L. Wilson, Cami N. Christopher, Amber J. Normann, Oscar Barnes, Jordan D. Lesansee, Gyuhwan Choi, Christina M. Dieli-Conwright
Summary: Anthracycline-induced cardiotoxicity is a serious clinical problem that needs to be addressed. Exercise therapy, as a non-pharmacological intervention, has potential benefits in preventing and managing cardiotoxicity caused by anthracyclines. However, the underlying mechanisms of exercise and its implementation in clinical settings to improve long-term cardiovascular outcomes require further research.
FRONTIERS IN CARDIOVASCULAR MEDICINE
(2022)
Article
Cardiac & Cardiovascular Systems
Joerg Herrmann, Daniel Lenihan, Saro Armenian, Ana Barac, Anne Blaes, Daniela Cardinale, Joseph Carver, Susan Dent, Bonnie Ky, Alexander R. Lyon, Teresa Lopez-Fernandez, Michael G. Fradley, Sarju Ganatra, Giuseppe Curigliano, Joshua D. Mitchell, Giorgio Minotti, Ninian N. Lang, Jennifer E. Liu, Tomas G. Neilan, Anju Nohria, Rupal O'Quinn, Iskra Pusic, Charles Porter, Kerry L. Reynolds, Kathryn J. Ruddy, Paaladinesh Thavendiranathan, Peter Valent
Summary: The discipline of Cardio-Oncology focuses on the cardiovascular care of cancer patients and the management of cardiovascular complications of cancer therapies. This document provides consensus definitions for common cardiovascular toxicities and aims to improve communication and outcomes in clinical practice and research.
EUROPEAN HEART JOURNAL
(2022)
Review
Cardiac & Cardiovascular Systems
Jean C. Bikomeye, Janee D. Terwoord, Janine H. Santos, Andreas M. Beyer
Summary: Anticancer therapies can have cardiotoxic side effects, with mitochondrial damage being a key factor. Further research is needed to understand the secondary signaling events that occur in response to such damage, as mitochondria also play important roles in other pathologies.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY
(2022)
Review
Oncology
Drishti Tolani, Julia Wilcox, Sharvari Shyam, Neha Bansal
Summary: As chemotherapy improves, understanding the effects on the cardiovascular system is increasingly important. Cardiotoxicity is a major determinant of morbidity and mortality in cancer survivors. New imaging modalities and biomarkers may detect subclinical cardiotoxicity earlier. Dexrazoxane remains the most effective therapy for preventing anthracycline-induced cardiomyopathy. Neurohormonal modulating drugs have not been effective in preventing cardiotoxicity. Advanced cardiac therapies, like heart transplant, should be considered for cancer survivors with end-stage HF. Research on genetic associations may produce treatments to reduce cardiovascular morbidity and mortality.
CURRENT TREATMENT OPTIONS IN ONCOLOGY
(2023)
Review
Medicine, General & Internal
Nadine Norton, Raegan M. Weil, Pooja P. Advani
Summary: Anthracyclines, widely used in oncology, have a significant side effect of cardiotoxicity, but progress is being made in predicting high-risk individuals and developing individualized cardioprotective plans through methodology and pharmacogenetic studies.
JOURNAL OF CLINICAL MEDICINE
(2021)
Article
Cardiac & Cardiovascular Systems
Michal Laufer-Perl, Orly Arias, Svetlana Sirota Dorfman, Guy Baruch, Ehud Rothschild, Gil Beer, Shira Peleg Hasson, Yaron Arbel, Zach Rozenbaum, Yan Topilsky, Livia Kapusta
Summary: This study aimed to evaluate changes in left atrial strain (LAS) during Anthracycline (ANT) therapy in female breast cancer patients and to assess the correlation between LAS and routine echocardiographic diastolic parameters. The results showed significant reductions in LASr and LASc are frequent during ANT therapy, with significant correlation to routine echocardiographic diastolic parameters, indicating a potential role in early detection of cardiotoxicity.
INTERNATIONAL JOURNAL OF CARDIOLOGY
(2021)
Review
Medicine, General & Internal
Jean Kim, Yoshito Nishimura, Jakrin Kewcharoen, James Yess
Summary: This study found a significant reduction in the incidence of chemotherapy-induced cardiomyopathy and the degree of left ventricular ejection fraction decline in patients who received concurrent statin therapy compared to those who received chemotherapy alone.
JOURNAL OF CLINICAL MEDICINE
(2021)
Review
Biochemistry & Molecular Biology
Anurag Choksey, Kerstin N. Timm
Summary: The long-term cardiovascular complications of cancer therapy are increasing due to the rising number of cancer survivors. This article discusses the underexplored field of cancer therapy-induced cardiotoxicity (CTIC), which is caused by chemotherapy, targeted anti-cancer agents, and radiation therapy. The article emphasizes the need for diagnostics that can detect CTIC before functional decline occurs and reviews the metabolic alterations and mechanisms involved in the development of CTIC. The potential methods for diagnosing and predicting CTIC and the therapeutic potential of manipulating cardiac metabolism are also evaluated.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Article
Cardiac & Cardiovascular Systems
Fabian Muehlberg, Markus Kornfeld, Leonora Zange, Saeed Ghani, Annette Reichardt, Peter Reichardt, Jeanette Schulz-Menger
Summary: This study aims to assess the subclinical changes in functional and morphologic myocardial MR parameters early in the course of high-dose anthracycline treatment. The results suggest that an early increase in myocardial T2 times 48 hours after the first anthracycline treatment may predict the subsequent development of anthracycline-induced cardiomyopathy. Additionally, a decrease in native T1 times was observed regardless of the development of cardiomyopathy in high-dose anthracycline therapy.
Article
Cardiac & Cardiovascular Systems
Sukhjinder Singh Nijjer
CARDIOLOGY CLINICS
(2024)
Article
Cardiac & Cardiovascular Systems
Doosup Shin, Seung Hun Lee, David Hong, Ki Hong Choi, Joo Myung Lee
Summary: Post-PCI physiologic assessment has significant prognostic value and plays a role in functionally optimized PCI. Investigating the reasons behind suboptimal post-PCI physiologic results using pressure-wire pullback tracings and/or intravascular imaging is important. Functionally optimized PCI should be considered at the beginning of the procedure, and careful PCI planning using pre-PCI physiologic evaluation can increase the probability of achieving it.
CARDIOLOGY CLINICS
(2024)
Article
Cardiac & Cardiovascular Systems
Sonal Pruthi, Emaad Siddiqui, Nathaniel R. Smilowitz
CARDIOLOGY CLINICS
(2024)
Review
Cardiac & Cardiovascular Systems
Robert D. Safian
CARDIOLOGY CLINICS
(2024)
Article
Cardiac & Cardiovascular Systems
Adam Bland, Eunice Chuah, William Meere, Thomas J. Ford
Summary: CMD remains a challenging condition to manage due to its heterogeneous pathophysiology, presentation, and response to therapy. Awareness of CMD is improving, but there is a lack of randomized trials for therapy. Invasive assessment of the coronary microcirculation can improve patient-centered outcomes. Beta-blockers are still the cornerstone of therapy for angina due to CMD, while non-pharmacological interventions play a central role in management.
CARDIOLOGY CLINICS
(2024)
Article
Cardiac & Cardiovascular Systems
Samer Fawaz, Christopher M. Cook
CARDIOLOGY CLINICS
(2024)
Article
Cardiac & Cardiovascular Systems
Nils P. Johnson
Summary: From the four recent RCTs on FFR published or presented in 2021, we have learned several important lessons: study design should focus on discordant decisions; composite endpoints for PCI should prioritize vessel-level outcomes over mortality; initial PCI must be considered when calculating the total amount of TVR; ultrahigh rates of FFR<0.8 do not influence treatment decisions based on angiography; and although PCI is a reasonable option, CABG yields better outcomes for patients with severe multivessel disease.
CARDIOLOGY CLINICS
(2024)
Article
Cardiac & Cardiovascular Systems
Tobin Joseph, Michael Foley, Rasha Al-Lamee
CARDIOLOGY CLINICS
(2024)
Article
Cardiac & Cardiovascular Systems
David M. Tehrani, Arnold H. Seto
Summary: Accurate interpretation of hemodynamic indices like FFR and NHPRs is crucial with their increasing use. The choice between FFR and NHPRs depends on specific clinical and procedural scenarios, and data on their use in special clinical situations is limited.
CARDIOLOGY CLINICS
(2024)
